DoD Non-Dilutive Funding Extends AP-SA02 Phase 3 for SAB Therapy
Armata reports an additional $3.7M in non-dilutive DoW funding for AP-SA02 Phase 3 targeting complicated SAB (MSSA/MRSA). Cumulative DoW support reaches about $32.4M, signaling government backing and reduced dilution risk. Phase 3 initiation is slated for 2H 2026, following positive Phase 2a results and ongoing collaboration with DoW.
View signal analysis